Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.

Investigational new drugs - 1 Feb 2012

Pithavala Yazdi K, Tong Warren, Mount Janessa, Rahavendran Sadayappan V, Garrett May, Hee Brian, Selaru Paulina, Sarapa Nenad, Klamerus Karen J

Abstract excerpt

OBJECTIVE: Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation. Co-administration with CYP inhibitors may increase systemic exposure to axitinib and alter its safety profile. This study evaluated changes in axitinib plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Drug Interactions

Share to Indazoles

Share to Single-Blind Method

Source

Open in PubMed Open full text

Identifiers

PMID: 20740300
DOI: 10.1007/s10637-010-9511-6
PMCID: PMC3256319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.PMID 20740300Read ↗

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.Semantic proximity Read ↗

Population pharmacokinetic analysis of axitinib in healthy volunteers.Semantic proximity Read ↗

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.Semantic proximity Read ↗

In Vitro Kinetic Characterization of Axitinib Metabolism.Semantic proximity Read ↗

Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.Semantic proximity Read ↗

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.Semantic proximity Read ↗

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.Semantic proximity Read ↗

Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.Semantic proximity Read ↗

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.Semantic proximity Read ↗

Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.Semantic proximity Read ↗

Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.Semantic proximity Read ↗

Drug-Drug Interaction Potential of SH-1028, a Third-generation EGFR-TKI: In Vitro and Clinical TrialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.